Stock Watch: Protocol Changes Preface Poor Trial Outcomes

Few If Any Changes To Clinical Trials Are Good

It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

I remember an uncomfortable project team meeting as a commercial representative on a big pharma development program. The meeting was convened to discuss and remedy the dismal recruitment rate for a Phase IIb clinical trial. My clinical operations colleagues were wary about the work required to widen the recruitment criteria and increase the number of study sites so that more patients were enrolled. I on the other hand was concerned that broadening the inclusion criteria would also dilute efficacy across the new patient population. The conclusion of the discussion was to terminate the development because, as it was pointed out, very slow recruitment typically means that the original target patient population and commercial opportunity was much smaller than was first thought. Recently, companies have been attributing slow clinical trial recruitment to the pandemic, although Addex Therapeutics Ltd.’s extension and then termination of its clinical study could also just have been a euphemism for the drug’s lack of efficacy. (Also see "Syncona Biotechs Face Up To Trial Delays Over COVID-19" - Scrip, 23 March, 2020.)

I first saw the then private biotech company Sunesis Pharmaceuticals, Inc. in early 2001. Despite boasting a number of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Stock Watch

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By 

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By 

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By 

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.

More from Business

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By 

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.